NICE Recommends Nivolumab for Adjuvant Treatment of Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
More evidence on nivolumab is being collected
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1538 results
FDA Approves Ravulizumab-cwvz for Paroxysmal Nocturnal Haemoglobinuria
Approval is based on results from two open-label, randomised, active-controlled, non-inferiority phase III studies
FDA Approves Romiplostim for Paediatric Patients with Immune Thrombocytopenia
Approval is based on results from two double-blind placebo-controlled clinical trials
EMA Recommends Extension of Existing Paediatric Indications for Dasatinib
New indication concerns the treatment of newly diagnosed Ph+ ALL in combination with chemotherapy
Patient Privacy and Big Data
Tackling legal and ethical challenges that big data brings
FDA Approves Cabozantinib for Hepatocellular Carcinoma
Approval is based on results from the CELESTIAL trial
FDA Approves Longer-acting Calaspargase Pegol-mknl for ALL
FDA Approves Longer-acting Calaspargase Pegol-mknl for ALL
NICE Issues Diagnostics Guidance on Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer
EndoPredict, Oncotype DX Breast Recurrence Score and Prosigna are recommended, while MammaPrint and IHC4+C are not
FDA Approves Tagraxofusp-erzs for Blastic Plasmacytoid Dendritic Cell Neoplasm
CD123-directed cytotoxin is indicated in adults and in paediatric patients
Spotlight on Digital Medicine
A series of articles published in the Nature Medicine highlight new technologies that are transforming medicine and healthcare
FDA Approves Pembrolizumab for Merkel Cell Carcinoma
Approval is based on results from the KEYNOTE-017 study
FDA Approves Olaparib for First-line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer
Patients should be selected for therapy based on an FDA-approved companion diagnostic